FDA approves first self-administered flu vaccine | KXAN Austin
WEB15 hours ago · The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has s…
MedImmune Receives FDA Approval for Self-Administered Flu …
WEB3 days ago · By Connor Hart. AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare provider ...
FDA Approves First Flu Vaccine You Give Yourself at Home - U.S. News …
WEB3 days ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... MedImmune's FluMist was first approved in 2003 for folks ages 5 to 49 to prevent flu, and then ...
FDA approves at-home FluMist administration | CIDRAP
WEB2 days ago · The Food and Drug Administration (FDA) today announced that it has approved self- or caregiver-administered FluMist, making it the first flu vaccine that doesn’t have to be administered by a healthcare provider. In a statement, the FDA said that MedImmune, the maker of FluMist, plans to offer the vaccine through a …
MedImmune - Wikipedia
WEBUnder the contract with HHS, MedImmune will continue to make its seasonal FluMist vaccine and also develop a vaccine targeted specifically at the novel H1N1 virus. [5] MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1. [11]
FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver ...
WEB2 days ago · Today, the U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes ...
AstraZeneca retires Medimmune name amid sales turnaround
WEBFeb 14, 2019 · After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing restructuring efforts.
AstraZeneca near deal to buy MedImmune - WSJ | Reuters
WEBBritain's AstraZeneca Plc <AZN.L> is near a deal to buy U.S. biotechnology company MedImmune Inc. <MEDI.O> in a transaction that could be worth more than $13 billion, the Wall Street Journal...
AstraZeneca oncology portfolio strengthened as MedImmune
WEBOct 15, 2013 · AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate...
AstraZeneca buys MedImmune for $15bn - The Times
WEBAstraZeneca has agreed a $15 billion (£7.8 billion) acquisition that it hopes will boost its biotech business and underpin the growth of its drugs pipeline. The Anglo-Swedish drugs maker said it had.